Cargando…

Elevated Liver Enzymes in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease

Background Non-alcoholic fatty liver disease (NAFLD) is emerging as the most common chronic liver condition. Approximately 70% of type 2 diabetes mellitus (T2DM) patients have a fatty liver; the progression to non-alcoholic steatohepatitis (NASH) dramatically increases the risks of cirrhosis and hep...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandal, Amrendra, Bhattarai, Bikash, Kafle, Paritosh, Khalid, Mazin, Jonnadula, Saikiran K, Lamicchane, Jenny, Kanth, Rajan, Gayam, Vijay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347442/
https://www.ncbi.nlm.nih.gov/pubmed/30697502
http://dx.doi.org/10.7759/cureus.3626
_version_ 1783389936381067264
author Mandal, Amrendra
Bhattarai, Bikash
Kafle, Paritosh
Khalid, Mazin
Jonnadula, Saikiran K
Lamicchane, Jenny
Kanth, Rajan
Gayam, Vijay
author_facet Mandal, Amrendra
Bhattarai, Bikash
Kafle, Paritosh
Khalid, Mazin
Jonnadula, Saikiran K
Lamicchane, Jenny
Kanth, Rajan
Gayam, Vijay
author_sort Mandal, Amrendra
collection PubMed
description Background Non-alcoholic fatty liver disease (NAFLD) is emerging as the most common chronic liver condition. Approximately 70% of type 2 diabetes mellitus (T2DM) patients have a fatty liver; the progression to non-alcoholic steatohepatitis (NASH) dramatically increases the risks of cirrhosis and hepatocellular carcinoma. The aim of our study was to assess the profile of liver enzymes in subjects with T2DM and NAFLD. Method This was a cross-sectional clinic-based study in patients with T2DM. An ultrasonography of the abdomen was done in all patients in order to examine the presence of a fatty liver. Body mass index (BMI), lipid profile, and liver enzymes were also analyzed in all patients. Institutional Review Board (IRB) approval was provided by the National Academy of Medical Sciences, Bir Hospital, Nepal. Unpaired t-test, Chi-square/Fisher's exact test (for categorical variables), and the Pearson/Spearman correlation test were used to find a significant difference, association, and correlation between two or more groups, respectively. The Statistical Package for Social Sciences (SPSS)® Statistics, version 16 (IBM SPSS Statistics, Armonk, NY) was used to analyse the data. Results The study was carried out in 210 patients, and out of the 210 patients, 119 (56.6%) were male and 91 (43.3%) were female. The patients were divided into two groups, i.e., the normal alanine aminotransferase (ALT) group and the elevated ALT group. The mean age of the patients was 56.28 ± 12.3 years in the normal alanine aminotransferase (ALT) group and 58.6 ± 24.7 in the elevated ALT group. The number of T2DM patients with a fatty liver was 117 (55.7%) and those with a non-fatty liver was 93 (44.2%) based on an ultrasonography scan. Subjects with NAFLD had a significantly higher ALT (p < 0.001) but no significant rise in serum aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), and alkaline phosphatase (ALP) levels. The area under the receiver operating characteristic (AUROC) curve for the prediction of fatty liver based solely on the ALT was 0.84 with the confidence interval (CI) between 0.76 and 0.92 (p < 0.05). Conclusions Non-alcoholic fatty liver disease is highly prevalent in patients with T2DM. Timely diagnosis and management of the abnormal liver parameters may help to minimize liver-related morbidity and mortality in the diabetic population.
format Online
Article
Text
id pubmed-6347442
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-63474422019-01-29 Elevated Liver Enzymes in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease Mandal, Amrendra Bhattarai, Bikash Kafle, Paritosh Khalid, Mazin Jonnadula, Saikiran K Lamicchane, Jenny Kanth, Rajan Gayam, Vijay Cureus Endocrinology/Diabetes/Metabolism Background Non-alcoholic fatty liver disease (NAFLD) is emerging as the most common chronic liver condition. Approximately 70% of type 2 diabetes mellitus (T2DM) patients have a fatty liver; the progression to non-alcoholic steatohepatitis (NASH) dramatically increases the risks of cirrhosis and hepatocellular carcinoma. The aim of our study was to assess the profile of liver enzymes in subjects with T2DM and NAFLD. Method This was a cross-sectional clinic-based study in patients with T2DM. An ultrasonography of the abdomen was done in all patients in order to examine the presence of a fatty liver. Body mass index (BMI), lipid profile, and liver enzymes were also analyzed in all patients. Institutional Review Board (IRB) approval was provided by the National Academy of Medical Sciences, Bir Hospital, Nepal. Unpaired t-test, Chi-square/Fisher's exact test (for categorical variables), and the Pearson/Spearman correlation test were used to find a significant difference, association, and correlation between two or more groups, respectively. The Statistical Package for Social Sciences (SPSS)® Statistics, version 16 (IBM SPSS Statistics, Armonk, NY) was used to analyse the data. Results The study was carried out in 210 patients, and out of the 210 patients, 119 (56.6%) were male and 91 (43.3%) were female. The patients were divided into two groups, i.e., the normal alanine aminotransferase (ALT) group and the elevated ALT group. The mean age of the patients was 56.28 ± 12.3 years in the normal alanine aminotransferase (ALT) group and 58.6 ± 24.7 in the elevated ALT group. The number of T2DM patients with a fatty liver was 117 (55.7%) and those with a non-fatty liver was 93 (44.2%) based on an ultrasonography scan. Subjects with NAFLD had a significantly higher ALT (p < 0.001) but no significant rise in serum aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), and alkaline phosphatase (ALP) levels. The area under the receiver operating characteristic (AUROC) curve for the prediction of fatty liver based solely on the ALT was 0.84 with the confidence interval (CI) between 0.76 and 0.92 (p < 0.05). Conclusions Non-alcoholic fatty liver disease is highly prevalent in patients with T2DM. Timely diagnosis and management of the abnormal liver parameters may help to minimize liver-related morbidity and mortality in the diabetic population. Cureus 2018-11-23 /pmc/articles/PMC6347442/ /pubmed/30697502 http://dx.doi.org/10.7759/cureus.3626 Text en Copyright © 2018, Mandal et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Mandal, Amrendra
Bhattarai, Bikash
Kafle, Paritosh
Khalid, Mazin
Jonnadula, Saikiran K
Lamicchane, Jenny
Kanth, Rajan
Gayam, Vijay
Elevated Liver Enzymes in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease
title Elevated Liver Enzymes in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease
title_full Elevated Liver Enzymes in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease
title_fullStr Elevated Liver Enzymes in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease
title_full_unstemmed Elevated Liver Enzymes in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease
title_short Elevated Liver Enzymes in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease
title_sort elevated liver enzymes in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347442/
https://www.ncbi.nlm.nih.gov/pubmed/30697502
http://dx.doi.org/10.7759/cureus.3626
work_keys_str_mv AT mandalamrendra elevatedliverenzymesinpatientswithtype2diabetesmellitusandnonalcoholicfattyliverdisease
AT bhattaraibikash elevatedliverenzymesinpatientswithtype2diabetesmellitusandnonalcoholicfattyliverdisease
AT kafleparitosh elevatedliverenzymesinpatientswithtype2diabetesmellitusandnonalcoholicfattyliverdisease
AT khalidmazin elevatedliverenzymesinpatientswithtype2diabetesmellitusandnonalcoholicfattyliverdisease
AT jonnadulasaikirank elevatedliverenzymesinpatientswithtype2diabetesmellitusandnonalcoholicfattyliverdisease
AT lamicchanejenny elevatedliverenzymesinpatientswithtype2diabetesmellitusandnonalcoholicfattyliverdisease
AT kanthrajan elevatedliverenzymesinpatientswithtype2diabetesmellitusandnonalcoholicfattyliverdisease
AT gayamvijay elevatedliverenzymesinpatientswithtype2diabetesmellitusandnonalcoholicfattyliverdisease